AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (77.1%), Germany (2.3%), Canada (2%), Japan (1.9%), China (1.7%), France (1.4%), Spain ( 0.9%), Italy (0.9%), Australia (0.9%), Brazil (0.8%), United Kingdom (0.8%) and others (9.3%).

Employees

50,000

Sector

Pharmaceuticals

Calendar

2024-10-23 - BioProcess International Asia

Related indices

S&P 500

More about the company

Quotes

Date	Price	Change	Volume
24-09-05	192.86 $	-2.11%	5,902,786
24-09-04	197.01 $	-0.34%	4,214,441
24-09-03	197.69 $	+0.70%	4,872,587
24-08-30	196.31 $	+0.58%	3,820,802
24-08-29	195.18 $	-0.11%	4,538,372

Delayed Quote Nyse, September 05, 2024 at 04:00 pm EDT

More quotes

Income Statement and Estimates

More financial data

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

192.86USD

Average target price

196.30USD

Spread / Average Target

+1.78%

Consensus

Profit revisions

Estimate revisions

Quarterly earnings, Rate of surprise

Company calendar

Market Closed - Nyse Other stock markets 04:00:02 2024-09-05 pm EDT			5-day change	1st Jan Change
192.86 ^USD	-2.11%		-1.19%	+24.45%

Sep. 04	AbbVie's VrayLAR®? (Cariprazine) Receives Positive Reimbursement Recommendation by Canada's Drug Agency for the Treatment of Schizophrenia	CI
Sep. 04	Medincell: program with AbbVie enters pre-clinical phase	CF

Capitalization	341B	P/E ratio 2024 *	37.5x	P/E ratio 2025 *	27.1x
Enterprise value	396B	EV / Sales 2024 *	7.11x	EV / Sales 2025 *	6.61x
Free-Float	96.39%	Yield 2024 *	3.23%	Yield 2025 *	3.34%

AbbVie's VrayLAR®? (Cariprazine) Receives Positive Reimbursement Recommendation by Canada's Drug Agency for the Treatment of Schizophrenia	Sep. 04	CI
Medincell: program with AbbVie enters pre-clinical phase	Sep. 04	CF
Medincell Announces Progress in the Development of Its Products Portfolio and R&D Pipeline	Sep. 03	CI
Leerink Partners Adjusts Price Target on AbbVie to $206 From $196, Maintains Market Perform Rating	Aug. 28	MT
BioArctic AB Announces Study results from phase 1 studies with exidavnemab published in The Journal of Clinical Pharmacology	Aug. 27	CI
Evercore ISI Raises Price Target on AbbVie to $192 From $180, Keeps Outperform Rating	Aug. 26	MT
Market on edge, anticipating Powell's play	Aug. 23
Analysis-Ozempic on Wall Street's list for 2027 Medicare drug negotiations	Aug. 23	RE
Piper Sandler Adjusts Price Target on AbbVie to $209 From $196, Maintains Overweight Rating	Aug. 23	MT
Analyst recommendations: Abbvie, Cbre group, Snowflake, Intuit, Lockheed Martin...	Aug. 23
AbbVie: positive opinion for UC in the UK	Aug. 23	CF
New cycle and Capex evolution	Aug. 20
AbbVie, Genmab Lymphoma Treatment Gets European Commission Marketing Authorization	Aug. 19	DJ

Leerink Partners Adjusts Price Target on AbbVie to $206 From $196, Maintains Market Perform Rating	Aug. 28	MT
Evercore ISI Raises Price Target on AbbVie to $192 From $180, Keeps Outperform Rating	Aug. 26	MT
Piper Sandler Adjusts Price Target on AbbVie to $209 From $196, Maintains Overweight Rating	Aug. 23	MT
Analyst recommendations: Abbvie, Cbre group, Snowflake, Intuit, Lockheed Martin...	Aug. 23
Morgan Stanley Adjusts Price Target on AbbVie to $218 From $211, Maintains Overweight Rating	Aug. 12	MT

AbbVie Inc. Stock

Equities

ABBV

US00287Y1091

Pharmaceuticals

Valuation: AbbVie Inc.

Chart: AbbVie Inc.

Latest news: AbbVie Inc.

Last Transcript: AbbVie Inc.

Analysts' recommendations: AbbVie Inc.

Press Releases: AbbVie Inc.

News in other languages: AbbVie Inc.

Quotes and Performance

Course Extremes

Managers and Directors: AbbVie Inc.

ETFs: AbbVie Inc.

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Ratings

Analysts' Consensus

Quarterly earnings, Rate of surprise

AbbVie's VRAYLAR® (cariprazine) Receives Positive Reimbursement Recommendation by Canada's Drug Agency for the Treatment of Schizophrenia	Sep. 04	AQ
AbbVie - SkinMedica Revolutionizes Skin Hydration with the Introduction of HA5 Hydra Collagen Replenish + Restore Hydrator	Aug. 28	AQ
SkinMedica Introduces HA5 Hydra Collagen Replenish + Restore Hydrator	Aug. 27	AQ
AbbVie Awards Scholarships to 45 U.S. Students Living With Chronic Immune-Mediated Diseases	Aug. 27	PR
SkinMedica® Revolutionizes Skin Hydration with the Introduction of HA5® Hydra Collagen Replenish + Restore Hydrator	Aug. 27	PR

Medincell : entrée préclinique d'un programme avec AbbVie	Sep. 04
Wall Street foire sa rentrée	Sep. 04
En Direct des Marchés : Pernod Ricard, Commerzbank, Schneider, Galderma, Nvidia, Saipem, BYD...	Sep. 04
Borsa di Italia: Wall Street rovina il suo rimbalzo	Sep. 04
Bolsa de Madrid: Wall Street estropea su remontada	Sep. 04

1 day	+0.87%
1 week	-1.19%
Current month	-1.76%
1 month	+4.61%
3 months	+16.57%
6 months	+7.65%
Current year	+24.45%

Director	Title	Age	Since
Robert Michael CEO	Chief Executive Officer	53	11-12-31
Scott Reents DFI	Director of Finance/CFO	57	12-12-31
Roopal Thakkar CTO	Chief Tech/Sci/R&D Officer	-	02-12-31

Manager	Title	Age	Since
Richard Gonzalez CHM	Chairman	70	12-12-31
Roxanne Austin BRD	Director/Board Member	63	12-12-31
William Burnside BRD	Director/Board Member	72	12-12-31

Name	Weight	AuM	1st Jan change	Investor Rating
FIRST TRUST MORNINGSTAR DIVIDEND LEADERS ETF (CAD-HEDGED) - CAD	7.12%	7 M€	+14.94%	-
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (YEN-HEDGED) ETF - JPY	6.85%	18 M€	+7.76%	-
RIZE MEDICAL CANNABIS AND LIFE SCIENCES UCITS ETF ACC - USD	6.26%	13 M€	-.--%

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
ABBVIE INC.	-2.11%	-1.19%	+32.01%	+72.78%	341B
ELI LILLY AND COMPANY	-3.55%	-2.92%	+63.52%	+251.69%	822B
NOVO NORDISK A/S	-1.18%	-6.41%	+32.29%	+175.67%	583B
JOHNSON & JOHNSON	-1.42%	+0.46%	+2.68%	-5.74%	397B
MERCK & CO., INC.	+2.41%	+0.96%	+10.31%	+53.49%	301B
ASTRAZENECA PLC	+0.33%	-5.11%	+18.76%	+45.70%	256B
ROCHE HOLDING AG	-0.72%	-4.35%	+8.84%	-25.27%	262B
NOVARTIS AG	-0.99%	-4.30%	+12.06%	+16.86%	236B
AMGEN INC.	-1.90%	-2.01%	+27.70%	+43.29%	174B
PFIZER, INC.	+0.42%	-0.73%	-19.42%	-39.13%	162B
Average	-0.22%	-2.11%	+18.87%	+58.93%	353.35B
Weighted average by Cap.	-0.22%	-2.29%	+27.66%	+101.35%

	2024 *	2025 *
Net sales	55.7B	58.57B
Net income	8.84B	11.51B
Net Debt	55.65B	46.64B